review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1093/ANNONC/MDQ304 |
P8608 | Fatcat ID | release_oufhemodb5bk7jw4w3xsxaqqmq |
P698 | PubMed publication ID | 20566473 |
P5875 | ResearchGate publication ID | 44690982 |
P2093 | author name string | B Thürlimann | |
M Joerger | |||
J Huober | |||
P2860 | cites work | Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial | Q43241014 |
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer | Q43250044 | ||
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer | Q43270036 | ||
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial | Q46736552 | ||
Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies | Q47402211 | ||
Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy | Q47587986 | ||
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller | Q24641848 | ||
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 | Q24657145 | ||
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. | Q37123529 | ||
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? | Q43231278 | ||
P433 | issue | 1 | |
P921 | main subject | breast cancer | Q128581 |
P1104 | number of pages | 7 | |
P304 | page(s) | 17-23 | |
P577 | publication date | 2010-06-20 | |
P1433 | published in | Annals of Oncology | Q326122 |
P1476 | title | Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? | |
P478 | volume | 22 |
Q46842669 | Does comparative effectiveness research promote rationing of cancer care? |
Q35947005 | Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials |
Q35653774 | Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales? |
Q37595263 | HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. |
Q38041467 | Management of small HER2 overexpressing tumours |
Q34400615 | Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer |
Q42571051 | Targeted therapy in HER2-positive breast cancer |
Q91834210 | The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution |
Q51673307 | The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. |
Q38973381 | Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
Search more.